Trevi Therapeutics, Inc.
TRVI
$16.64
-$0.18-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 32.07% | 35.08% | 30.47% | 26.53% | 19.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.60% | 3.29% | -4.26% | 6.50% | 19.34% |
| Operating Income | -15.60% | -3.29% | 4.26% | -6.50% | -19.34% |
| Income Before Tax | -8.09% | 3.59% | 10.68% | -3.48% | -22.07% |
| Income Tax Expenses | -48.94% | -111.76% | -103.23% | -6.90% | -327.27% |
| Earnings from Continuing Operations | -8.05% | 3.67% | 10.75% | -3.48% | -21.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.05% | 3.67% | 10.75% | -3.48% | -21.99% |
| EBIT | -15.60% | -3.29% | 4.26% | -6.50% | -19.34% |
| EBITDA | -15.66% | -3.32% | 4.27% | -6.51% | -19.39% |
| EPS Basic | 18.54% | 28.85% | 32.70% | 16.80% | -7.35% |
| Normalized Basic EPS | 18.51% | 28.83% | 32.68% | 16.85% | -7.38% |
| EPS Diluted | 18.54% | 28.85% | 32.70% | 16.80% | -7.35% |
| Normalized Diluted EPS | 18.51% | 28.83% | 32.68% | 16.85% | -7.38% |
| Average Basic Shares Outstanding | 29.55% | 34.50% | 33.60% | 25.93% | 15.58% |
| Average Diluted Shares Outstanding | 29.55% | 34.50% | 33.60% | 25.93% | 15.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |